The efficacy of tranexamic acid for decreasing blood loss in open myomectomy

Abstract

Uterine fibroids are the most prominent benign tumor in females. Recently, attention has focused on the use of tranexamic acid to reduce blood loss if given prophylactically at myomectomy. We conducted this study to evaluate the efficacy and safety of perioperative tranexamic acid in blood loss reduction in many patients with uterine fibroids undergoing myomectomy et al Basrah maternity and children’s hospital in Basrah. The study was conducted at Basrah maternity and child hospital for the period from the 1st of January 2020 till the 1st of January 2023. It includes 98 (48 control who received no medication before the surgery and 50 cases patients who received IV 1 g tranexamic acid at the skin incision) ladies who planned to undergo open myomectomy. The duration of surgery was calculated in minutes, Intraoperative, postoperative, and total blood loss was measured. Abdominal pain was the commonest presenting symptom of fibroid in both case and control group (56.0% and 52.1%, respectively) and followed by AUB then the infertility. Regarding the intraoperative, postoperative, and total blood loss there’s a significant significant difference between case and control group. The operation time and hospital stay were significantly less among case group who received IV tranexamic acid. Tranexamic acid is a safe drug to reduce hemorrhage in women with fibroid subjected to open myomectomy and it has no major adverse effects.